Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCATGet Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $11.79.

Several equities research analysts recently issued reports on the stock. Stephens raised their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Evercore ISI lifted their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. boosted their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Citigroup lifted their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th.

Check Out Our Latest Stock Report on HCAT

Insider Activity at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 19,268 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the transaction, the general counsel now directly owns 72,250 shares of the company’s stock, valued at $601,120. This trade represents a 21.05 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the sale, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,551 shares of company stock worth $532,105 in the last three months. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. First Light Asset Management LLC raised its stake in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after acquiring an additional 3,221,408 shares during the period. Millennium Management LLC raised its position in shares of Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Nepsis Inc. grew its position in shares of Health Catalyst by 67.9% in the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after buying an additional 851,448 shares during the last quarter. Fred Alger Management LLC purchased a new position in Health Catalyst during the 3rd quarter worth approximately $6,858,000. Finally, Portolan Capital Management LLC purchased a new position in shares of Health Catalyst during the third quarter worth approximately $5,402,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Price Performance

Shares of HCAT stock opened at $6.97 on Friday. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The stock has a market cap of $424.11 million, a price-to-earnings ratio of -5.16 and a beta of 1.31. The business’s fifty day moving average is $8.13 and its 200 day moving average is $7.45. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCATGet Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the previous year, the business earned ($0.22) earnings per share. Health Catalyst’s revenue was up 3.5% compared to the same quarter last year. Research analysts expect that Health Catalyst will post -0.33 EPS for the current fiscal year.

About Health Catalyst

(Get Free Report

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

Featured Stories

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.